Paolo Ghia, MD, PhD

Professor of Medical Oncology
Università Vita Salute and IRCCS Ospedale San Raffaele, Italy

Poster(s):

• 1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses

• 1014 - Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance

• 1016 - Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis

• 1101 - An immuno-(epi)genomic classification of chronic lymphocytic leukemia refines outcome prediction

• 1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation

• 1202 - Advanced 3D culture system revealed the dynamic regulation of Podoplanin in CLL cells within the microenvironment

• 1207 - In vitro investigation of the phenotype of CLL cells during trafficking and homing in a 3D-printed bioreactor

• 1208 - Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people

• 1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience

• 1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study

• 1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1419 - SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D

• 1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL

• 1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL

• 1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• 1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study

• 1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study

• 1902 - Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study